Indeed, the presence of cytotoxic CD4+ T cells in pre-treatment tumors, based on expression of a gene signature associated with these cells, was predictive of clinical response to anti-PD-L1 in bladder cancer (Oh et al., 2020). Here, CD4 is linked to urinary bladder carcinoma.